Biomunex signs licensing agreement with Sanofi for development of antibodies Medical Dialogues Bureau19 Jan 2019 9:15 AM ISTUnder the terms of the agreement, Sanofi will have access to Biomunex proprietary technology to generate and optimize bi- and multi-specific antibody...
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal Farhat Nasim9 Jan 2019 9:15 AM ISTSanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the...
Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in Immuno-Oncology Ruby Khatun Khatun9 Sept 2017 9:57 AM ISTKENILWORTH, N.J. & MUNICH: Merck, known as MSD outside the United States and Canada, and Rigontec announced that Merck will acquire...
